Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Universal Chimeric Antigen Receptor-Modified AT19 Cells by Chengdu USino Technology Biology for Hematological Tumor: Likelihood of Approval
Universal Chimeric Antigen Receptor-Modified AT19 Cells is under clinical development by Chengdu USino Technology Biology and currently in Phase I...
Universal Chimeric Antigen Receptor-Modified AT19 Cells by Chengdu USino Technology Biology for Unspecified B-Cell Lymphomas: Likelihood of Approval
Universal Chimeric Antigen Receptor-Modified AT19 Cells is under clinical development by Chengdu USino Technology Biology and currently in Phase I...
Gene Therapy to Target CD19 for Hematological Tumors by Chengdu USino Technology Biology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD19 for Hematological Tumors is under clinical development by Chengdu USino Technology Biology and currently in...
Gene Therapy to Target CD19 for Hematological Tumors by Chengdu USino Technology Biology for Hematological Tumor: Likelihood of Approval
Gene Therapy to Target CD19 for Hematological Tumors is under clinical development by Chengdu USino Technology Biology and currently in...